Hiv-1 envelope glycosylation and the signal peptide

Gregory S. Lambert, Chitra Upadhyay

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


The RV144 trial represents the only vaccine trial to demonstrate any protective effect against HIV-1 infection. While the reason(s) for this protection are still being evaluated, it serves as justification for widespread efforts aimed at developing new, more effective HIV-1 vaccines. Advances in our knowledge of HIV-1 immunogens and host antibody responses to these immunogens are crucial to informing vaccine design. While the envelope (Env) protein is the only viral protein present on the surface of virions, it exists in a complex trimeric conformation and is decorated with an array of variable N-linked glycans, making it an important but difficult target for vaccine design. Thus far, efforts to elicit a protective humoral immune response using structural mimics of native Env trimers have been unsuccessful. Notably, the aforementioned N-linked glycans serve as a component of many of the epitopes crucial for the induction of potentially protective broadly neutralizing antibodies (bnAbs). Thus, a greater understanding of Env structural determinants, most criti-cally Env glycosylation, will no doubt be of importance in generating effective immunogens. Recent studies have identified the HIV-1 Env signal peptide (SP) as an important contributor to Env glyco-sylation. Further investigation into the mechanisms by which the SP directs glycosylation will be important, both in the context of understanding HIV-1 biology and in order to inform HIV-1 vaccine design.

Original languageEnglish
Article number176
Pages (from-to)1-19
Number of pages19
Issue number2
StatePublished - Feb 2021


  • Broadly neutralizing antibodies
  • Glycosylation
  • HIV envelope
  • HIV-1
  • PNGS
  • Signal peptide
  • Vaccine


Dive into the research topics of 'Hiv-1 envelope glycosylation and the signal peptide'. Together they form a unique fingerprint.

Cite this